ACAD
Acadia Pharmaceuticals Inc.
September 25, 2026 · market open
- Rarity
- 1.76
- Peak move
- −7.10%
- Float cap
- $3.7B
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on neurological and rare diseases. It markets NUPLAZID (pimavanserin) in the United States for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide) for Rett syndrome, including in the United States, Canada, and Israel. It also develops product candidates for Alzheimer's disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor, and Huntington's disease.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
15 events · 1 from SEC or newswire · 0 timed with the move- Key event
analyst_ratingNeedham analyst Ami Fadia lowered her price target on Acadia Pharmaceuticals to $35 from $41, keeping a Buy rating, and pushed out the estimated remlifanserin launch timeline by a year after the RADIANT Phase 2 results.
- Key event
analyst_ratingDeutsche Bank analyst David Hoang lowered his price target on Acadia Pharmaceuticals to $31 from $38 while keeping a Buy rating after the RADIANT Phase 2 topline data narrowly missed statistical significance at the 60 mg dose.
analyst_ratingCitigroup lowered its price target on Acadia Pharmaceuticals to $33 from $40 while maintaining a Buy rating after remlifanserin missed the primary endpoint in the Phase 2 RADIANT trial.
executive_remarkOn an investor call discussing the RADIANT Phase 2 data, Acadia CEO Catherine Owen Adams said she was encouraged by the results and that the molecule is worth investing in for Phase 3, while R&D head Elizabeth Thompson said the company is weighing refining Phase 3 enrollment for higher baseline psychosis.
- Key event
clinical_readoutAcadia reported Phase 2 RADIANT topline results for remlifanserin in Alzheimer's disease psychosis: the 60 mg dose missed the primary SAPS-H+D endpoint (effect size 0.26, p=0.0603) but met the key secondary CGI-S-ADP endpoint (effect size 0.37, nominal p=0.0077), and the 30 mg arm will be dropped from Phase 3.
analyst_ratingH.C. Wainwright analyst Ananda Ghosh lowered his price target on Acadia Pharmaceuticals to $33 from $37 while keeping a Buy rating, citing the missed RADIANT Phase 2 primary endpoint for remlifanserin and uncertainty around Phase 3 timelines.
analyst_ratingTD Cowen reiterated its Buy rating on Acadia Pharmaceuticals on September 24, 2026.
analyst_ratingOppenheimer reiterated a Market Perform rating on Acadia Pharmaceuticals (ACAD) with a $25.00 price target on September 23, 2026, calling the upcoming Phase 2 RADIANT topline data for remlifanserin in Alzheimer's disease psychosis the key near-term catalyst, expected in September or October.
analyst_ratingDeutsche Bank set a $29.00 price target on Acadia Pharmaceuticals, lowered to $29 from $35 while maintaining a Buy rating.
analyst_ratingLeerink said Acadia's ACP-101 primary-endpoint miss in Prader-Willi syndrome was 'disappointing but expected', noting low expectations given an earlier Phase 3 failure, and kept an Outperform rating on the shares.
clinical_readoutAcadia announced that its Phase 3 COMPASS PWS trial of intranasal carbetocin (ACP-101) did not meet its primary endpoint on change from baseline to Week 12 on the HQ-CT and showed no separation on any secondary endpoint; the 175-patient trial enrolled ages 5-30, and Acadia will not investigate the drug further.
analyst_ratingNeedham lowered its price target on Acadia Pharmaceuticals to $28.00 from $30.00 while maintaining a Buy rating following the Phase 3 COMPASS PWS failure of ACP-101.
analyst_ratingOppenheimer analyst Matthew Hershenhorn maintained a Hold rating on Acadia Pharmaceuticals with a $21.00 price target after the ACP-101 Phase 3 COMPASS PWS failure, while Stifel Nicolaus's Paul Matteis also issued a Hold and TD Cowen maintained Buy.
insider_saleAcadia director Elizabeth A. Garofalo sold 1,600 shares for a total of $41,552, part of a quarter in which insider selling increased relative to earlier in the year.
analyst_ratingUBS analyst Ashwani Verma reiterated a Buy rating on Acadia Pharmaceuticals with a $39.00 price target; shares opened at $24.38 that day.